Free tool
FAERS Monitor: Pulmotech Maa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 210089 or its brand name (Pulmotech Maa, Technetium Tc99m Albumin Aggregated). Reports on generic versions are filed under their own applications.
Reports
3
Serious
1
33% of reports
Hospitalization
0
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dizziness1
- muscular weakness1
- product preparation error1
- radioisotope scan abnormal1
- syncope1
- ventilation/perfusion scan abnormal1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2021 | 2 |
| 2024 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,156 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| ventilation/perfusion scan abnormal | 1 | 259927.9 | 50210.2 | 62,660 |
| radioisotope scan abnormal | 1 | 9940.6 | 2002.9 | 2,481 |
| product preparation error | 1 | 341.3 | 68.9 | 84 |
| syncope | 1 | 70.1 | 14.1 | 17 |
| muscular weakness | 1 | 61.7 | 12.4 | 15 |
| dizziness | 1 | 14.1 | 2.8 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.